AB308 is an anti-TIGIT antibody that is FcR-enabled.

SparkCures ID 411
Developed By Arcus Biosciences, Inc.
Generic Name AB308

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.